|
1.
|
|
9 p, 981.6 KB |
A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis
/
Piñana, J.L. (Hospital Universitari i Politècnic La Fe (València)) ;
Perez-Pitarch, A. (Hospital Clínico Universitario de València) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Hernandez-Boluda, J.C. (Fundación de Investigación INCLIVA) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ;
Terol, M.J. (Fundación de Investigación INCLIVA) ;
Queraltó, Josep M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Vima, Jaume (Hospital Universitari Vall d'Hebron) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Ferriols-Lisart, R. (Hospital Clínico Universitario de València) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Solano, C. (Universitat de València) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
There is a paucity of data evaluating acute kidney injury (AKI) incidence and its relationship with the tacrolimus-sirolimus (Tac-Sir) concentrations in the setting of reduced-intensity conditioning (RIC) after allogeneic stem cell transplantation (allo-HSCT). [...]
2017 -  10.1016/j.bbmt.2017.03.035
Biology of blood and marrow transplantation, Vol. 23 Núm. 7 (july 2017) , p. 1177-1185
|
|
|
2.
|
|
12 p, 983.1 KB |
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients : the better study
/
Fernandez Rivera, Constantino (Complejo Hospitalario Universitario de A Coruña) ;
Calvo Rodríguez, María (Complejo Hospitalario Universitario de A Coruña) ;
Poveda, José Luís (Hospital Universitari i Politècnic La Fe (València)) ;
Pascual, Julio (Pascual Santos) (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Crespo, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Gomez, Gonzalo (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Cabello Pelegrin, Sheila (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Paul, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Lauzurica, Ricardo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Perez Mir, Mònica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Moreso, Francesc (Hospital Universitari Vall d'Hebron) ;
Perelló, Manel (Hospital Universitari Vall d'Hebron) ;
Andres, Amado (Hospital 12 de Octubre (Madrid)) ;
González, Esther (Hospital 12 de Octubre (Madrid)) ;
Fernandez, Ana (Hospital Universitario Ramón y Cajal (Madrid)) ;
Mendiluce, Alicia (Hospital Universitario Clínico de Valladolid) ;
Fernández Carbajo, Beatriz (Hospital Universitario Clínico de Valladolid) ;
Sanchez Fructuoso, Ana (Hospital Universitario Clínico San Carlos (Madrid)) ;
Calvo, Natividad (Hospital Universitario Clínico San Carlos (Madrid)) ;
Suarez, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Bernal Blanco, Gabriel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Osuna, Antonio (Hospital Universitario Virgen de las Nieves (Granada)) ;
Ruiz-Fuentes, M. Carmen (Hospital Universitario Virgen de las Nieves (Granada)) ;
Melilli, Edoardo (Hospital Universitari de Bellvitge) ;
Montero, Nuria (Hospital Universitari de Bellvitge) ;
Ramos, Ana (Hospital Universitario Fundación Jiménez Díaz) ;
Fernández, Beatriz (Hospital Universitario Fundación Jiménez Díaz) ;
López, Verónica (Universidad de Málaga) ;
Hernandez, Domingo (Universidad de Málaga) ;
Universitat Autònoma de Barcelona
Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. [...]
2021 - 10.1111/ctr.14550
Clinical Transplantation, Vol. 36 (december 2021)
|
|
|
3.
|
|
20 p, 1.3 MB |
Early prognostic performance of miR155-5p monitoring for the risk of rejection : Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients
/
Quintairos, Luis (Hospital Clínic i Provincial de Barcelona) ;
Colom, Helena (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ;
Millan, Olga (Instituto de Salud Carlos III) ;
Fortuna, Virginia (Hospital Clínic i Provincial de Barcelona) ;
Espinosa, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Guirado, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Budde, K (Charité - Universitätsmedizin Berlin) ;
Sommerer, Claudia (Heidelberg University Hospital (Alemanya)) ;
Lizana, Ana (Hospital Clínic i Provincial de Barcelona) ;
Lopez-Pua, Yolanda (Hospital Clínic i Provincial de Barcelona) ;
Brunet, Mercè (Instituto de Salud Carlos III)
Previous results from our group and others have shown that urinary pellet expression of miR155-5p and urinary CXCL-10 production could play a key role in the prognosis and diagnosis of acute rejection (AR) in kidney transplantation patients. [...]
2021 - 10.1371/journal.pone.0245880
PloS one, Vol. 16 Núm. 1 January (january 2021) , p. e0245880
|
|
|
4.
|
|
13 p, 1.4 MB |
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
/
Fernández-Juárez, Gema (Hospital Universitario Fundación Alcorcón) ;
Rojas-Rivera, Jorge E. (Hospital Universitario Fundación Jiménez Díaz) ;
Logt, Anne-Els van de (Radboud University Medical Center) ;
Justino, Joana (Université Côte d'Azur. Institut de Pharmacologie Moléculaire et Cellulaire (Valbonne, França)) ;
Sevillano Prieto, Angel Manuel (Hospital Universitario 12 de Octubre (Madrid)) ;
Caravaca-Fontan, Fernando (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Ávila, Ana (Hospital Universitari Doctor Peset (València)) ;
Rabasco, Cristina (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Cabello, Virginia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Varela, Alfonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Díaz Encarnación, Montserrat Mercedes (Institut d'Investigació Biomèdica Sant Pau) ;
Martín-Reyes, Guillermo (Hospital Regional Universitario de Málaga) ;
Goicoechea, Marian (Hospital General Universitario Gregorio Marañón) ;
Quintana, Luis F. (Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
Gómez-Martino, Juan Ramón (Hospital San Pedro de Alcántara) ;
Cao, Mercedes (Complejo Hospitalario Universitario de A Coruña) ;
Rodríguez-Moreno, Antolina (Hospital Clínico San Carlos (Madrid)) ;
Rivas, Begoña (Hospital Universitario La Paz (Madrid)) ;
Galeano Alvarez, Cristina (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bonet, Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romera, Ana (Hospital General de Ciudad Real) ;
Shabaka, Amir (Hospital Universitario Fundación Alcorcón) ;
Plaisier, Emmanuelle (Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique (Niça, França)) ;
Espinosa, Mario (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Egido de los Rios, Jesus (Hospital Universitario Fundación Jiménez Díaz) ;
Segarra-Medrano, Alfonso (Hospital Universitari Vall d'Hebron) ;
Lambeau, Gérard (Institut de Pharmacologie Moléculaire et Cellulaire (Valbonne, França)) ;
Ronco, Pierre (Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique (Niça, França)) ;
Wetzels, Jack (Radboud University Medical Center) ;
Praga, Manuel (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Caravaca-Fontan, Fernando (Hospital Universitario 12 de Octubre (Madrid)) ;
Trujillo, Hernando (Hospital Universitario 12 de Octubre (Madrid)) ;
Gutiérrez, Eduardo (Hospital Universitario 12 de Octubre (Madrid)) ;
Ortiz, Alberto (Hospital Universitario Fundación Jiménez Díaz) ;
Goicoechea, Marian (Hospital General Universitario Gregorio Marañón) ;
Verdalles, Úrsula (Hospital General Universitario Gregorio Marañón) ;
Segarra, Alfons (Hospital Universitari Vall d'Hebron) ;
Perea, Lara (Hospital Universitari Vall d'Hebron) ;
Valera, Ildefonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Martín, Mónica (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Pérez Valdivia, Miguel Angel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Blasco, Miquel Angel (Hospital Clínic i Provincial de Barcelona) ;
López Muñiz, Andrés (Complejo Hospitalario Universitario de A Coruña) ;
Malek, Tamara (Hospital Universitari Doctor Peset (València)) ;
DaSilva Santos, Iara ;
Bonet, Jordi (Institut Germans Trias i Pujol) ;
Navarro, Maruja Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Huerta, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodríguez-Paternina, Ezequiel (Hospital Universitario de Getafe (Madrid)) ;
Vigil, Ana (Hospital Universitario Severo Ochoa) ;
Alcázar, Roberto (Hospital Universitario Infanta Leonor) ;
Paraíso, Vicente (Hospital Universitario del Henares ( Madrid)) ;
Barrio, Vicente (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
Hofstra, Julia (Radboud University Medical Center) ;
Universitat Autònoma de Barcelona
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating treatment with corticosteroids and cyclophosphamide in inducing persistent remission in these patients. [...]
2021 - 10.1016/j.kint.2020.10.014
Kidney International, Vol. 99 Núm. 4 (april 2021) , p. 986-998
|
|
|
5.
|
|
12 p, 2.3 MB |
Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression : results of the IMAGEN study
/
Sommerer, Claudia (Heidelberg University Hospital (Alemanya)) ;
Brunet, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Budde, K. (Charité University Hospital Berlin) ;
Millán, O. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Guirado, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Glander, P. (Charité University Hospital Berlin) ;
Meuer, S. (Institute of Immunology. University Hospital Heidelberg) ;
Zeier, M. (Heidelberg University Hospital (Alemanya)) ;
Giese, Thomas (Heidelberg University Hospital (Alemanya))
Aims: Calcineurin inhibitors (CNI) have a small therapeutic window, and drug monitoring is required. Pharmacokinetic monitoring does not correlate sufficiently with clinical outcome. Therefore, the expression of nuclear factor of activated T cells (NFAT)-regulated genes in the peripheral blood has been suggested as a potentially useful immune monitoring tool to optimize CNI therapy. [...]
2021 - 10.1111/bcp.14794
British Journal of Clinical Pharmacology, Vol. 87 Núm. 10 (october 2021) , p. 3851-3862
|
|
|
6.
|
|
14 p, 3.2 MB |
Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors
/
Carreras-Planella, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Juega-Mariño, Javier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Taco, Omar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cañas, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Franquesa, Marcella (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lauzurica, Ricardo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Borràs i Serres, Francesc Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. [...]
2020 - 10.3390/ijms21207569
International journal of molecular sciences, Vol. 21 (october 2020)
|
|
|
7.
|
|
14 p, 1.0 MB |
Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies : The Influence of TAC Exposure and Metabolism
/
Chamoun, Betty (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Torres, Irina B. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gabaldón, Alejandra (Hospital Universitari Vall d'Hebron) ;
Sellarés Nadal, Joana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Perelló, Manel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Castellà Fernández, Eva (Hospital Universitari Vall d'Hebron) ;
Guri, Xavier (Hospital Universitari Vall d'Hebron) ;
Salcedo, Maite (Hospital Universitari Vall d'Hebron) ;
Toapanta, Néstor (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cidraque, Ignacio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreso, Francesc (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seron, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina)
The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C), coefficient of variation of tacrolimus (CV-TAC-C), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. [...]
2021 - 10.3390/jcm10010141
Journal of clinical medicine, Vol. 10 (january 2021)
|
|
|
8.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
|
9.
|
|
12 p, 537.1 KB |
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation : The 2019 Expert Consensus From the Transplantion Society Working Group
/
Schinstock, Carrie A. (Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN) ;
Mannon, Roslyn B. (Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL) ;
Budde, K (Charité - Universitätsmedizin Berlin) ;
Chong, Anita S. (Section of Transplantation, Department of Surgery, The University of Chicago, Chicago, IL) ;
Haas, Mark (Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA) ;
Knechtle, Stuart (Duke Transplant Center, Department of Surgery, Duke University School of Medicine, Durham, NC) ;
Lefaucheur, Carmen (Université de Paris, Department of Transplantation, Saint Louis Hospital, Paris, France) ;
Montgomery, Robert A. (NYU Langone Transplant Institute) ;
Nickerson, Peter (Transplant Immunology Laboratory, Shared Health and Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada) ;
Tullius, Stefan G. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Ahn, Curie (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea) ;
Askar, Medhat (Baylor University Medical Center, Transplant Immunology, Dallas, TX) ;
Crespo, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Chadban, Steven J. (Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia) ;
Feng, Sandy (Department of Surgery, University of California San Francisco, San Francisco, CA) ;
Jordan, Stanley C. (Cedars-Sinai Medical Center (West Hollywood, Estats Units d'Amèrica)) ;
Man, Kwan (The University of Hong Kong. Department of Surgery) ;
Mengel, Michael (University of Alberta. Department of Laboratory Medicine and Pathology) ;
Morris, Randall E. (Stanford University School of Medicine) ;
O'Doherty, Inish (Critical Path Institute, Tucson, AZ) ;
Ozdemir, Binnaz H. (Baskent University (Ankara, Turquia)) ;
Seron, Daniel (Hospital Universitari Vall d'Hebron) ;
Tambur, Anat R. (Northwestern University (Chicago, Estats Units d'Amèrica). Comprehensive Transplant Center) ;
Tanabe, Kazunari (Tokyo Women's Medical University. Department of Urology) ;
Taupin, Jean-Luc (Université Paris Diderot) ;
O'Connell, Philip J. (University of Sydney) ;
Universitat Autònoma de Barcelona
With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. [...]
2020 - 10.1097/TP.0000000000003095
Transplantation, Vol. 104 (april 2020) , p. 911-922
|
|
|
10.
|
|
12 p, 571.6 KB |
Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus
/
Torres, Armando (Hospital Universitario de Canarias (La Laguna)) ;
Hernández, Domingo (Instituto de Investigación Biomédica de Málaga) ;
Moreso, Francesc (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seron, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Burgos, María Dolores (Instituto de Investigación Biomédica de Málaga) ;
Pallardó, Luis M. (Hospital Universitari Doctor Peset (València)) ;
Kanter, Julia (Hospital Universitari Doctor Peset (València)) ;
Díaz Corte, Carmen (Hospital Universitario Central de Asturias) ;
Rodríguez, Minerva (Hospital Universitario Central de Asturias) ;
Díaz Gómez, Juan Manuel (Institut d'Investigació Biomèdica Sant Pau) ;
Silva, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Valdes, Francisco (Complejo Hospitalario Universitario de A Coruña) ;
Fernández-Rivera, Constantino (Complejo Hospitalario Universitario de A Coruña) ;
Osuna, Antonio (Hospital Universitario Virgen de las Nieves (Granada)) ;
Gracia Guindo, María C. (Hospital Universitario Virgen de las Nieves (Granada)) ;
Gómez Alamillo, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Ruiz, Juan C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Marrero Miranda, Domingo (Hospital Universitario de Canarias (La Laguna)) ;
Pérez-Tamajón, Lourdes (Hospital Universitario de Canarias (La Laguna)) ;
Rodríguez, Aurelio (Hospital Universitario de Canarias (La Laguna)) ;
González-Rinne, Ana (Hospital Universitario de Canarias (La Laguna)) ;
Alvarez, Alejandra (Hospital Universitario de Canarias (La Laguna)) ;
Perez-Carreño, Estefanía (Hospital Universitario de Canarias (La Laguna)) ;
de la Vega Prieto, María José (Hospital Universitario de Canarias (La Laguna)) ;
Henriquez, Fernando (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Gallego Samper, Roberto (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Salido, Eduardo (Hospital Universitario de Canarias (La Laguna)) ;
Porrini, Esteban (Hospital Universitario de Canarias (La Laguna)) ;
Universitat Autònoma de Barcelona
Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). [...]
2018 - 10.1016/j.ekir.2018.07.009
Kidney International Reports, Vol. 3 (july 2018) , p. 1304-1315
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
